These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 20868350)

  • 1. Recent clinical aspects of hyperprolactinemia induced by antipsychotics.
    Milano W; D'Acunto CW; De Rosa M; Festa M; Milano L; Petrella C; Capasso A
    Rev Recent Clin Trials; 2011 Jan; 6(1):52-63. PubMed ID: 20868350
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Antipsychotic-drug-induced hyperprolactinemia: physiopathology, clinical features and guidance].
    Besnard I; Auclair V; Callery G; Gabriel-Bordenave C; Roberge C
    Encephale; 2014 Feb; 40(1):86-94. PubMed ID: 23928066
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antipsychotic-induced hyperprolactinaemia: mechanisms, clinical features and management.
    Haddad PM; Wieck A
    Drugs; 2004; 64(20):2291-314. PubMed ID: 15456328
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Hyperprolactinemia in mentally ill patients].
    Carvalho MM; Góis C
    Acta Med Port; 2011; 24(6):1005-12. PubMed ID: 22713195
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antipsychotic-induced Hyperprolactinemia in aging populations: Prevalence, implications, prevention and management.
    González-Rodríguez A; Labad J; Seeman MV
    Prog Neuropsychopharmacol Biol Psychiatry; 2020 Jul; 101():109941. PubMed ID: 32243999
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Switch to quetiapine in antipsychotic agent-related hyperprolactinemia.
    Keller R; Mongini F
    Neurol Sci; 2002 Dec; 23(5):233-5. PubMed ID: 12522680
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of NTRK2, DRD2 and ACE polymorphisms on prolactin levels in antipsychotic-treated patients with first-episode psychosis.
    Gassó P; Mas S; Bioque M; Cabrera B; Lobo A; González-Pinto A; Díaz-Caneja CM; Corripio I; Vieta E; Castro-Fornieles J; Sarró S; Mané A; Sanjuan J; Llerena A; Lafuente A; Saiz-Ruiz J; Bernardo M;
    J Psychopharmacol; 2018 Jun; 32(6):702-710. PubMed ID: 29767567
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hyperprolactinemia Induced by Antipsychotics: From Diagnosis to Treatment Approach.
    Milano W; Colletti C; Capasso A
    Endocr Metab Immune Disord Drug Targets; 2017; 17(1):38-55. PubMed ID: 28440197
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of antipsychotic-induced hyperprolactinemia on anthropometric measures, insulin sensitivity and lipid profile in patients with schizophrenia or related psychoses.
    Melkersson K; Berinder K; Hulting AL
    Neuro Endocrinol Lett; 2011; 32(4):428-36. PubMed ID: 21876517
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effects of atypical antipsychotics on serum prolactin levels.
    Hamner M
    Ann Clin Psychiatry; 2002 Sep; 14(3):163-73. PubMed ID: 12585566
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sexual dysfunction associated with neuroleptic-induced hyperprolactinemia improves with reduction in prolactin levels.
    Ahl J; Kinon BJ; Liu-Seifert H
    Ann N Y Acad Sci; 2004 Dec; 1032():289-90. PubMed ID: 15677431
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prolactin, hyperprolactinaemia and antipsychotic treatment: a review and lessons for treatment of early psychosis.
    Cookson J; Hodgson R; Wildgust HJ
    J Psychopharmacol; 2012 May; 26(5 Suppl):42-51. PubMed ID: 22472310
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antipsychotic-induced hyperprolactinemia and sexual dysfunction.
    Compton MT; Miller AH
    Psychopharmacol Bull; 2002; 36(1):143-64. PubMed ID: 12397853
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prolactin awareness: an essential consideration for physical health in schizophrenia.
    Montejo AL
    Eur Neuropsychopharmacol; 2008 May; 18 Suppl 2():S108-14. PubMed ID: 18346598
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Positron emission tomography measurement of dopamine D₂ receptor occupancy in the pituitary and cerebral cortex: relation to antipsychotic-induced hyperprolactinemia.
    Arakawa R; Okumura M; Ito H; Takano A; Takahashi H; Takano H; Maeda J; Okubo Y; Suhara T
    J Clin Psychiatry; 2010 Sep; 71(9):1131-7. PubMed ID: 20361897
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Second-generation and newly approved antipsychotics, serum prolactin levels and sexual dysfunctions: a critical literature review.
    De Hert M; Detraux J; Peuskens J
    Expert Opin Drug Saf; 2014 May; 13(5):605-24. PubMed ID: 24697217
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of the dopamine agonists bromocriptine and cabergoline in the management of risperidone-induced hyperprolactinemia in patients with psychotic disorders.
    Tollin SR
    J Endocrinol Invest; 2000 Dec; 23(11):765-70. PubMed ID: 11194712
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aripiprazole-Associated Hypoprolactinemia in the Clinical Setting.
    Sogawa R; Shimomura Y; Minami C; Maruo J; Kunitake Y; Mizoguchi Y; Kawashima T; Monji A; Hara H
    J Clin Psychopharmacol; 2016 Aug; 36(4):385-7. PubMed ID: 27281387
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antipsychotics-induced hyperprolactinemia and screening for macroprolactin.
    Ruljancic N; Bakliza A; Vuk Pisk S; Geres N; Matic K; Ivezic E; Grosic V; Filipcic I
    Biochem Med (Zagreb); 2021 Feb; 31(1):010707. PubMed ID: 33380894
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Psychiatric Patients with Antipsychotic Drug-Induced Hyperprolactinemia and Menstruation Disorders.
    Takechi K; Yoshioka Y; Kawazoe H; Tanaka M; Takatori S; Kobayashi M; Matsuoka I; Yanagawa H; Zamami Y; Imanishi M; Ishizawa K; Tanaka A; Araki H
    Biol Pharm Bull; 2017; 40(10):1775-1778. PubMed ID: 28966250
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.